XOMA Corp(NASDAQ:XOMA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $443.00K. Analysts estimated a revenue of $900.00K. Earnings per share were $-0.15. Analysts had estimated an EPS of $-0.12.
XOMA Corp (XOMA) made into the market gainers list on Fridays trading session with the shares advancing 0.97% or 0.0059 points. Due to strong positive momentum, the stock ended at $0.6128, which is also near the day’s high of $0.62. The stock began the session at $0.5952 and the volume stood at 2,63,811 shares. The 52-week high of the shares is $2.03 and the 52 week low is $0.44. The company has a current market capitalization of $74 M and it has 12,05,83,797 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Mar 22, 2016, Thomas M. Burns (VP, Finance & Chief Financial) sold 19,249 shares at $0.79 per share price.Also, On Mar 22, 2016, James R Neal (VP Business Development) sold 19,813 shares at $0.79 per share price.On Mar 22, 2016, Paul D Rubin (Sr. VP Clinical Dev. & CMO) sold 24,194 shares at $0.79 per share price, according to the Form-4 filing with the securities and exchange commission.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead product candidate gevokizumab is a potent humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate posterior or pan-uveitis (NIU) and Behcet’s disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program which includes EYEGUARD-A (patients with active NIU) EYEGUARD-B (patients with Behcet’s disease uveitis outside of the United States) and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).